계명대학교 의학도서관 Repository

Assessment of quality o life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment

Metadata Downloads
Author(s)
Yongsik JungSoo Jung LeeJuneyoung LeeWoo Chul NohSeok Jin NamByeong-Woo ParkYoung Tae BaeSung-Soo KangHeung Kyu ParkJung-Han YoonJe Ryong KimSe Hun ChoLee Su KimSung Hoo JungChol Wan LimSung Yong KimHo Yong ParkJeongyoon SongKwang Man LeeSung Hwan ParkJoon JeongHae Lin ParkSung Won KimBeom Seok KwakSun Hee KangYoung Up ChoGeum Hee GwakYong Lae ParkSang Wook KimSehwan HanByung In Moon
Keimyung Author(s)
Kang, Sun Hee
Department
Dept. of Surgery (외과학)
Journal Title
Journal of Breast Cancer
Issued Date
2018
Volume
21
Issue
2
Keyword
Breast neoplasmsLetrozoleQuality of lifeTreatment
Abstract
Purpose: There are few reports from Asian countries about the
long-term results of aromatase inhibitor adjuvant treatment for
breast cancer. This observational study aimed to evaluate the
long-term effects of letrozole in postmenopausal Korean women
with operable breast cancer. Methods: Self-reported quality of life
(QoL) scores were serially assessed for 3 years during adjuvant
letrozole treatment using the Korean version of the Functional
Assessment of Cancer Therapy-Breast questionnaires (version 3).
Changes in bone mineral density (BMD) and serum cholesterol
levels were also examined. Results: All 897 patients received the
documented informed consent form and completed a baseline
questionnaire before treatment. Adjuvant chemotherapy was
administered to 684 (76.3%) subjects, and 410 (45.7%) and 396
(44.1%) patients had stage I and II breast cancer, respectively.
Each patient completed questionnaires at 3, 6, 12, 18, 24, 30,
and 36 months after enrollment. Of 897 patients, 749 (83.5%)
completed the study. The dropout rate was 16.5%. The serial trial
outcome index, the sum of the physical and functional wellbeing
subscales, increased gradually and significantly from
baseline during letrozole treatment (p<0.001). The mean serum
cholesterol level increased significantly from 199 to 205 after 36
months (p=0.042). The mean BMD significantly decreased from
–0.39 at baseline to –0.87 after 36 months (p<0.001). Conclusion:
QoL gradually improved during letrozole treatment. BMD and
serum cholesterol level changes were similar to those in Western
countries, indicating that adjuvant letrozole treatment is well tolerated
in Korean women, with minimal ethnic variation.
Keimyung Author(s)(Kor)
강선희
Publisher
School of Medicine (의과대학)
Citation
Yongsik Jung et al. (2018). Assessment of quality o life and safety in postmenopausal breast cancer patients receiving letrozole as an early adjuvant treatment. Journal of Breast Cancer, 21(2), 182–189. doi: 10.4048/jbc.2018.21.2.182
Type
Article
ISSN
1738-6756
DOI
10.4048/jbc.2018.21.2.182
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41080
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.